Is the Minister therefore saying that, in the event that adverse effects arose during the course of the clinical trial, there is now a requirement that the risk factors, as set out in the leaflet to which he referred, will reflect those adverse effects?
Care Bill [HL]
Proceeding contribution from
Lord Campbell-Savours
(Labour)
in the House of Lords on Monday, 10 June 2013.
It occurred during Committee of the Whole House (HL)
and
Debate on bills on Care Bill [HL].
About this proceeding contribution
Reference
745 c1505Session
2013-14Chamber / Committee
House of Lords chamberLibrarians' tools
Timestamp
2013-11-29 09:19:36 +0000
URI
http://hansard.intranet.data.parliament.uk/Lords/2013-06-10/13061047000118
In Indexing
http://indexing.parliament.uk/Content/Edit/1?uri=http://hansard.intranet.data.parliament.uk/Lords/2013-06-10/13061047000118
In Solr
https://search.parliament.uk/claw/solr/?id=http://hansard.intranet.data.parliament.uk/Lords/2013-06-10/13061047000118